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Boesenbergia rotunda is a herb from the Boesenbergia genera under the Zingiberaceae family. B. rotunda is widely found in Asian
countries where it is commonly used as a food ingredient and in ethnomedicinal preparations. The popularity of its ethnomedicinal
usage has drawn the attention of scientists worldwide to further investigate its medicinal properties. Advancement in drug design
and discovery research has led to the development of synthetic drugs from B. rotundametabolites via bioinformatics andmedicinal
chemistry studies. Furthermore, with the advent of genomics, transcriptomics, proteomics, and metabolomics, new insights on
the biosynthetic pathways of B. rotunda metabolites can be elucidated, enabling researchers to predict the potential bioactive
compounds responsible for the medicinal properties of the plant. The vast biological activities exhibited by the compounds
obtained from B. rotunda warrant further investigation through studies such as drug discovery, polypharmacology, and drug
delivery using nanotechnology.
1. Introduction
1.1. Boesenbergia rotunda and its Morphology. Boesenbergia
rotunda is a ginger species that grows in Southeast Asia,
India, Sri Lanka, and Southern China. This species belongs
to the family of Zingiberaceae. It was previously categorised
under the Kaempferia genus by Baker. However, it is now
classified under the Boesenbergia genus [1]. There are many
local synonyms to its name, such as Chinese keys or
Fingerroot in English, “Temu Kunci” in Malay and Krachai
or Krachai-Dang in Thailand. This plant has 8 diﬀerent
botanical names which are Boesenbergia cochinchinensis
(Gagnep.) Loes., Boesenbergia pandurata (Roxb.) Schltr.,
Curcuma rotunda L., Gastrochilus panduratus (Roxb.) Ridl.,
Gastrochilus rotundus (L.) Alston, Kaempferia cochinchi-
nensis Gagnep., Kaempferia ovate Roscoe, and Kaempferia
pandurata Roxb.; nonetheless it is currently known as
Boesenbergia rotunda (L.)Mansf. [2].
Boesenbergia is amongst the genera facing problems in
taxonomy classification due to its heterogeneous external
morphology. Despite this problem, currentmolecular studies
such as chloroplast DNA, nuclear internal transcribed spacer
(ITS), random amplified polymorphic DNA (RAPD), plastid
regions, pollen-based classifications, amplified fragment
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Figure 1: The morphology of yellow rhizome B. rotunda. Whole plant of B. rotunda (a), flower (b), and rhizomes (c) of B. rotunda.
length polymorphism (AFLP), and single strand confor-
mation polymorphism (SSCP) have made the classification
possible [3–7]. Eksomtramage and Boontum [8] have dis-
tinguished between B. rotunda and B. aﬀ. rotunda which
have similar morphology through chromosome analysis. The
chromosome count (2n) for B. rotunda and B. aﬀ. rotunda
was found to be 36 and 20, respectively. On the other hand,
the chromosome count for B. longipes, B. plicata, and B.
xiphostachya was 22. These results were reconfirmed in 2002
[8, 9]. The morphology of this ginger species has been well
characterized. It is a small perennial plant of about 15–40 cm
in height. Its leaves are broad and light green while the leaf
sheath is red. Each shoot consists of 3–5 elliptic-oblong-red
sheathed leaves of about 7–9 cm in width and 10–20 cm in
length. The underground portion of the plant consists of a
small globular shaped central subterraneous rhizome (1.5–
2.0 cm in diameter) from which several slender and long
tubers sprout all in the same direction like the fingers of
a hand, thus the common name fingerroot. The tubers are
about 1.0–1.5 cm thick in diameter and 5–10 cm long. The
tissue of the tuber is looser, softer, and more watery than the
central rhizome. Both the colour of the central rhizome and
the tubers are dependent on the variety of B. rotunda. The
yellow variety produces bright yellow rhizomes, while other
varieties produce red and black rhizomes. They are strongly
aromatic although diﬀerent from each other. The flowers are
scarlet and bloom throughout the year in tropical countries.
These beautiful flowers are usually hidden at the base of the
foliage, making them unnoticeable. The morphology of B.
rotunda is shown in Figure 1 [10, 11].
1.2. Ethnomedicinal Functions of B. rotunda. B. rotunda is
a common edible ingredient in many Asian countries such
as Malaysia, Thailand, Indonesia, India, and China. It is
normally cultivated at small home ranches and used as a
condiment in food such as curry and soup due to its aromatic
flavour, which promotes appetite. This herbal plant is also
used as a traditional medicine to treat illnesses such as
rheumatism, muscle pain, febrifuge, gout, gastrointestinal
disorders, flatulence, carminative, stomach ache, dyspepsia,
and peptic ulcer. In Indonesia, B. rotunda is typically used
to prepare “jamu,” a popular traditional tonic for women
after childbirth as well as a beauty aid for teenage girls and to
prevent leukorrhea [12]. The fresh rhizomes are used to treat
inflammatory diseases, such as dental caries, dermatitis, dry
cough and cold, tooth and gum diseases, swelling, wounds,
diarrhoea, and dysentery, and as a diuretic [13, 14]. Besides,
it is also used as an antifungal and antiparasitic agent to heal
fungal infections and eradicate helminth or round worms
in human intestine, respectively, as well as an antiscabies
agent to relieve skin itchiness from mite bites [15]. Referred
to as “Thai ginseng” in Thailand, this plant is used as an
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aphrodisiac among Thai folk. In addition, consumption of
its leaves has been shown to alleviate food allergies and
poisoning. Moreover, it has been used as self-medication
by AIDS patients in Thailand. Despite the lack of scientific
evidence to prove the ethnomedicinal uses of this ginger,
the success of current biological researches could potentially
explain the significance of its traditional usage.
1.3. Pharmaceutical and Medicinal Functions of B. rotunda.
Over the years, using various approaches and technologies,
researchers have successfully isolated an array of bioactive
compounds from B. rotunda Table 1. Nearly a hundred of
compounds were isolated and elucidated, ranging from the
flavonoid derivatives, chalcone derivatives, esters, kawains,
terpenes and terpenoids (see supplementary data 1 available
online at doi:10.1155/2012/473637 for more details about
the chemical structures of these isolated compounds). These
compounds have shown to exhibit great medicinal potential
(Table 2), which will be described in more details on the
following subtopics
2. Toxicity Tests
Given the high consumption of B. rotunda and the fact
that its safety has not been scientifically established, recent
studies have been focused on investigating the acute toxicity
of several extracts in vivo to determine the safety of this
plant for consumption. Saraithong et al. [40] demonstrated
that the ethanolic extract of B. rotunda was safe for con-
sumption as in vivo studies showed no significant changes
in the body weight of B. rotunda fed rats. Furthermore,
all haematological and histopathological parameters used
to evaluate the toxicity eﬀect did not show any adverse
changes [40]. Meanwhile, Charoensin et al. [41] reported
that two bioactive compounds from B. rotunda, pinostrobin
and pinocembrin, exhibited no mutagenic eﬀect or toxicity
towards Wister rats, further confirming the safety of its
consumption [41].
3. Antimicrobial Activities
3.1. Anti-Helicobacter pylori Activity. Helicobacter pylori is a
prominent Gram-negative bacteria that causes gastritis,
dyspepsia, and peptic ulcer and has been linked to the
development of gastric and colon cancer. Widespread claims
of the antimicrobial activities of B. rotunda prompted
scientists to further evaluate the potential of this plant in
preventing the infection of H. pylori. Pinostrobin and red
oil from the roots of B. rotunda were found to exhibit
anti-H. pylori activities against several diﬀerent isolates
of H. pylori [42]. The minimum inhibitory concentration
(MIC) for pinostrobin and the red oil were 125 μg/mL
and 150 μg/mL, respectively, which were comparable to the
positive control, clarithromycin (120 μg/mL); the minimum
bactericidal concentration (MBC) was determined to be
150 μg/mL and 175 μg/mL, respectively. Interestingly, while
both extracts inhibited H. pylori growth after 3 days, the
growth of other bacteria was inhibited by pinostrobin, but
not red oil [42]. The ethanolic extract of B. rotunda was
also reported to significantly reduce H. pylori infection in
Mongolian gerbils. Treated gerbils showed reduced acute
and chronic inflammation when fed with B. rotunda 3
weeks before being challenged with H. pylori, and 6 weeks
after. Therefore, flavonoid components of B. rotunda could
potentially serve as potential drug candidate for inhibition of
H. pylori infection [43].
3.2. Pathogenic and Spoilage Bacteria Inhibition Activities.
Pathogenic bacteria are a group of bacteria that induce
diseases in humans and plants. Spoilage bacteria are another
group of bacteria that cause food spoilage through fer-
mentation and decomposition of food products. There has
been a rising concern pertaining to food safety and diseases
caused by these pathogenic microorganisms, and hence, a
renewed interest in finding new antimicrobial agents to
combat these pathogens. In 2006, Pattaratanawadee et al.
studied the antimicrobial activity of diﬀerent extracts from
four Zingiberaceae species, namely, Zingiber oﬃcinale Rosc
(ginger), Curcuma longa Linn. (tumeric), Alpinia galangal
Stuntz (galangal), and Boesenbergia pandurata Schltr (finger-
root), on diﬀerent strains of pathogenic bacteria (Salmonella
enterica serotype Typhimurium: 2380, 2486, 2576, 2582,
Escherichia coli O157 :H7, Listeria monocytogenes: 101, 108,
310, Scott A, and V7, Bacillus cereus, and Staphylococcus
aureus) and spoilage bacteria (Lactobacillus plantarum: PD26
and PD110 and Lactobacillus cellobiosus: RE33, PD32, PD40,
PD55 and PD112). The MIC value for all plant extracts was
between 8 and 10% (v/v) against Gram-negative bacteria,
while fingerroot showed the highest inhibitory activity
against three pathogenic bacteria; L. monocytogenes, B. cereus,
and S. Aureus, with an MIC value of 0.2–0.4% (v/v).
Meanwhile, galangal extract showed strongest inhibition
against spoilage bacteria L. plantarum and L. cellobiosus,
with an MIC value of 4% (v/v). Both galangal (at 8%
(v/v)) and fingerroot (at 10% (v/v)) exhibited bactericidal
eﬀect against E. coli population (log cfu/mL) at 36 and 9
hours, respectively, while 8% (v/v) turmeric extract showed
bacteriostatic eﬀect [44]. Panduratin A of B. rotundawas also
found to possess antimicrobial activity against Staphylococcus
strains with MIC50 of 0.5 μg/mL and MIC90 of 1 μg/mL, both
comparable to the most potent antibiotic, vancomycin [45].
3.3. Anti-Amoebic Activity for HIV Patients. Amoebiasis is an
infection caused by the amoeba Entamoeba histolytica, which
typically causes acute and chronic diarrhoea in HIV patients,
regardless of whether they have AIDS. The use of local
medicinal plants to treat this disease is popular due in part to
its safety, ease of access and availability at low cost. A Previous
study on thirty nine extracts from twelve local herbs reported
that seven of the plant herbs, Murraya paniculata, Zingiber
zerumbet, Alpinia galanga, Barleria lupulina, B. rotunda,
Piper betle and Piper chaba, showed potent inhibition against
three E. histolytica strains; HTH-56:MUTM and strain HM1:
IMSS. The amoebas were cultured at 37◦C for 24 hours with
the plant extracts at a concentration of 1000 μg/mL, and the
results were determined by using inverted microscope. Based
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Table 1: Bioactive compounds that were extracted from the leaves, stems, and rhizomes of B. rotunda.
Compounds Isolated by
5-Hydroxy-7-methoxyflavanone (pinostrobin)
5,7-Dihydroxyflavanone (pinocembrin)
2′,6′-Dihydroxy-4′-methoxychalcone (pinostrobin chalcone)
2′,4′-Dihydroxy-6-methoxychalcone (Cardamonin)
Boesenbergin A
Jaipetch et al. [16]
5-Hydroxy-7-methoxyflavanone (pinostrobin)
5,7-Dimethoxyflavanone
5-Hydroxy-7-methoxyflavone
5-Hydroxy-7,4′-dimethoxyflavone
5,7-Dimethoxyflavone
5,7,4′-Trimethoxyflavone
5,7,3′,4′-Tetramethoxyflavone
5-Hydroxy-3,7-dimethoxyflavone
5-Hydroxy-3,7,4′-trimethoxyflavone
3,5,7-Trimethoxyflavone
5-Hydroxy-3,7,3′,4′-tetramethoxyflavone
Jaipetch et al. [17]
2,6-Dihydroxy-4-methoxyphenyl-[3′-methyl-2′-(3′′-methylbut-
2′′-enyl)-6′-phenylcyclohex-3′-enyl]methanone (panduratin A)
Rubranine
Pinostrobin
Boesenbergin A
Tuntiwachwuttikul et al. [18]
Boesenbergin B
Panduratin A
Mahidol et al. [19]
3,5,7,3′,4′-Pentamethoxyflavone
3,5,7,4′-Tetramethoxyflavone
5-Hydroxy-7,4′-dimethoxyflavanone
2′-Hydroxy-4′,6′-dimethoxychalcone
2′-Hydroxy-4,4′,6′-trimethoxychalcone
Herunsalee et al. 1987 [20]
(±)-Panduratin B1
(±)-Panduratin B2 Pancharoen et al. [21]
Pinostrobin
Pinocembrin
Alpinetin
Panduratin A
Tip-Pyang et al. [22]
2′,4′,6′-Trihydroxychalcone (Pinocembrin chalcone)
Cardamonin
Pinocembrin
5-Hydroxy-7-methoxyflavanone
(2,4,6-Trihydroxyphenyl)-[3′-methyl-2′-(3′′-methylbut-2′′-enyl)-
6′-phenylcyclohex-3′-enyl]methanone (4-Hydroxypanduratin A)
Panduratin A
Trakoontivakorn et al. [23]
Essential Oils
Camphor
Linalool
Camphene
α-Pinene
α-Terpineol
α-Phellandrene
γ-Terpinene
Methyl 3-phenylpropionate
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Table 1: Continued.
Compounds Isolated by
Geranyl formate
Geranyl propionate
Geraniol
Neral
Myrcene
Isoborneol
β-Pinene
Neryl acetate
Geranial
β-Thujaplicin
(E,E)-α-Farnesene
Borneol Jantan et al. [24]
Tricyclene
Terpinen-4-ol
Terpinolene
Myristicin
AlloOcimene
α-Thujene
(Z)-β-Ocimene
Sabinene
(E)-β-Ocimene
(Z)-Nerolidol
cis-Linalool oxide
3-Carene
δ-Elemene
(Z)-β-Farnesene
γ-Elemene
β-Elemene
(−)-4-Hydroxypanduratin A
(−)-Panduratin A
5,4′-Dihydroxy-7-methoxyflavanone (sakuranetin)
5-Hydroxy-7-methoxyflavanone
5,7-Dihydroxyflavanone
Dihydro-5,6-dehydrokawain
Tuchinda et al. [25]
Pinostrobin
Pinocembrin
Alpinetin
Cardamonin
Tewtrakul et al. [26, 27]
Camphor
Geraniol
Methyl cinnamate
Geranial (E-citral)
Zaeoung et al. [28]
5-Hydroxy-7-methoxyflavanone
(−)-Panduratin A
5,7-Dihydroxyflavone
Shindo et al. [29]
Pinostrobin chalcone
Cardamonin
(−)-4-Hydroxypanduratin A
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Table 1: Continued.
Compounds Isolated by
Panduratin C
Panduratin A
4-Hydroxypanduratin A
Cheenpracha et al. [30]
Helichrysetin
2′,4′,6′- Trihydroxydihydrochalcone (propiophenone)
Uvangoletin
Pinostrobin
Pinocembrin
Alpinetin
Cardamonin
Panduratin A
4-Hydroxypanduratin A
Tan et al., [31]
(2S)-6-Geranylpinostrobin
Geranyl-2,4-dihydroxy-6-phenethylbenzoate
2′,4′-Dihydroxy-3′-(1′′-geranyl)-6′-methoxychalcone
(1′R,2′S,6′R)-2-Hydroxyisopanduratin A
(2R)-8-Geranylpinostrobin
(±)-6-Methoxypanduratin A
(2S)-7,8-Dihydro-5-hydroxy-2-methyl-2-(4′′-methyl-3′′-
pentenyl)-8-phenyl-2H, 6H-benzo[1,2-b:5,4-b′]dipyran-6-one
(−)-Pinostrobin
Tectochrysin
5,6-Dehydrokawain
Cardamonin
(−)-Alpinetin
Flavokawain C
(−)-7,4′-Dihydroxy-5-methoxyflavanone
(−)-6-Geranylpinocembrin
Boesenbergin A
Panduratin A
Boesenbergin B
(±)-Isopanduratin A1
(−)-Pinocembrin
(−)-4-Hydroxypanduratin A
Nicolaioidesin B
Panduratin C
Isopanduratin A2
Win et al. [32]
Pinostrobin
Pinocembrin
Alpinetin
Cardamonin
Boesenbergin A
Ching et al. 2007 [33]; Sukari et
al. [34]
Prenylchalcones
(+)-Krachaizin A
(−)-Krachaizin A
(+)-Krachaizin B
(−)-Krachaizin B
(+)-Panduratin A Morikawa et al. [35]
(−)-Panduratin A
(+)-4-Hydroxypanduratin A
(−)-4-Hydroxypanduratin A
(+)-Isopanduratin A
(−)-Isopanduratin A
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Table 1: Continued.
Compounds Isolated by
Prenylflavonoids
Rotundaflavone Ia
Rotundaflavone Ib
Rotundaflavone iia
Rotundaflavone IIb
Flavanones and Others (12)
Pinostrobin
Pinocembrin
Alpinetin
7,4′-Dihydroxy-5-methoxyflavanone Morikawa et al. [35]
5,7-Dihydroxy-8-geranylflavanone
7-Methoxy-5-hydroxy-8-geranylflavanone
Cardamonin
2,6-Dihydroxy-4-methoxydihydrochalcone
2,4-Dihydroxy-6-phenethyl-benzoic acid methyl ester
Geranyl-2,4-dihydroxy-6-phenylbenzoate
5,6-Dehydrokawain
Geraniol
Essential oils
Monoterpenes hydrocarbons
1,8-Cineole
trans-Ocimene
Neryl acetate
β-Pinene
Oxygenated monoterpene derivatives
Borneol
β-Citronellol
Camphor
Bicyclo(2.2.1)heptan-2-ol
Methyl-n-nonanoate
trans-Geraniol Sukari et al. [36]
2-Cyclohexyethylacetate
3′,4′-Dimethoxyacetophenone
Rosephenone
Terpinyl valerate
N-Hexyl angelate
Sesquiterpene hydrocarbons
trans-Caryophyllene
1,3-Tetradecadiene
Miscellaneous compounds
Guaiacol
N-Hexanal
2-Isopropyl-4,5-dimethyloxazole
trans-2-Hexanyl-n-propionate
Cyclohexyl-n-propionate
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Table 1: Continued.
Compounds Isolated by
2-N-Pyroyl-4,5-dimethylthiazole
Ethyl benzoate
Guaiocol n-caproate
Geranyl benzoate Sukari et al. [36]
n-Butyl-n-pentadecanoate
n-Eicosane
Cinnamyl cinnamate
Panduratin B1
Panduratin B2
Panduratin D
Panduratin E
Win et al. [37]
Panduratin F
Panduratin G
Panduratin H
Panduratin I
Panduratin C
Panduratin A
Hydroxypanduratin A
Helichrysetin Trewtrakul et al. 2009
Propiophenone
Uvangoletin
Cardamonin
Pinostrobin
Pinocembrin Wangkangwan et al. [38]
Alpinetin
Polyphenols
Quercetin
Kaempferol
Naringin
Jing et al. [39]
Hesperidin
Caﬀeic acid
ρ-Coumaric acid
Chlorogenic acid
on the scoring standard of 1 to 4 with 1 indicating the highest
inhibition and 4 showing no inhibition, all the seven plants
scored a 1. The amoebic inhibition activities for these plants
were further tested whereby extracts with IC50 < 100 μg/mL
were deemed active. The chloroform extracts of A. galangal
(IC50 55.2 μg/mL), B. lupulina (IC50 78.5 μg/mL), B. rotunda
(IC50 45.8 μg/mL), P. betle (IC50 91.1 μg/mL) and P. chaba
(IC50 71.4 μg/mL) and the methanol extract of B. rotunda
(IC50 57.6 μg/mL) were all found to be active in inhibiting
propagation of amoebas [46].
4. Antiparasitic Activity
The inhibitory activity of B. rotunda against Giardia lamblia,
a protozoan parasite that causes giardiasis, was previously
demonstrated by Sawangjaroen and colleague in 2005. Giar-
diasis is the inflammation of the small intestine which causes
diarrhoea and nutrient deficiencies, although this parasitic
infection can cause chronic diarrhoea in HIV patients. The
chloroform extracts of B. rotunda and five other herbs, which
were Alpinia galanga, Eclipta prostrata, Piper betle, Piper
chaba, Zingiber zerumbet, and the methanol extracts of B.
rotunda and E. prostrata had an IC50 value between 20 μg/mL
and 100 μg/mL. A. galanga (chloroform extract) had the
highest inhibition activity with an MIC and IC50 values
of 125 μg/mL and 37.73 μg/mL, respectively [47]. Although
the eﬀect of these plant extracts paled in comparison to
metronidazole, a commercial antibiotic with an IC50 value
of 0.48 μg/mL, they are still considered as potential bioactive
compounds that could prevent giardiasis.
Evidence-Based Complementary and Alternative Medicine 9
Table 2: Inhibitory activities exhibited by B. rotunda extracts.
Inhibition Sources References
(1) Toxicity test Rhizomes
Saraithong et al. [40]
Charoensin et al. [41]
(2) Antimicrobial activities
(A) Anti-Helicobacter pylori activity Rhizomes
Bhamarapravati et al.
[42]
Mahady et al. [43]
(B) Pathogenic and spoilage bacteria
inhibition activities Rhizomes
Pattaratanawadee et al.
[44]
Rukayadi et al. [45]
(C) Antiamoebic activity for HIV patients Rhizomes Sawangjaroen et al. [46]
(3) Antiparasitic activity
Antigiardial activity Rhizomes Sawangjaroen et al. [47]
(4) Oral infections
(A) Inhibition of biofilm formation by oral
pathogens
Rhizomes
Limsuwan and
Voravuthikunchai [48]
Yanti et al., [49]
(B) Antiperiodontitis activity of B. rotunda extract Yanti et al., [49, 50]
(C) Inhibition of Candida albicans
Dried
plant
Cheeptham and Towers
[51]
Taweechaisupapong et
al. [52]
(D) Anticariogenic Rhizomes Hwang et al. [53, 54]
(E) Candida adhesion inhibitor Rhizomes
Sroisiri and Boonyanit,
[55]
(F) Antihalitosis Rhizomes
Hwang et al., (patented)
[56]
(5) Inhibition of biofilm formation by intestinal
pathogens
Rhizomes Rukayadi et al., [57]
(6) Antioxidant activities
(A) Inhibition of lipid peroxidation in brain Rhizomes Shindo et al., [29]
(B) Inhibition of oxidative damages by
tert-butylhydroperoxide (t-BHP) Rhizomes Sohn et al., [58]
(7) Antiulcer eﬀect Rhizomes Abdelwahab et al., [59]
(8) Obesity treatment Rhizomes Kim et al., [60]
(9) Antimutagenic eﬀect Rhizomes
Trakoontivakorn et al.,
[23]
(10) Antitumour necrosis factor alpha (anti-TNF-α) Rhizomes Morikawa et al., [35]
(11) Anticancer/antitumour
(A) Breast cancer and colon cancer prevention
Roots and
rhizomes
Kirana et al., [61]
Zaeoung et al., [28]
Kirana et al., [62]
Ling et al., [63]
(B) Inhibition of prostate cancers Rhizomes Yun et al., [64]
(C) Antilung cancer Rhizomes Cheah et al., [65]
(D) Antileukemia Rhizomes Sukari et al., [34]
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Table 2: Continued.
Inhibition Sources References
(12) Antifungal activities
(A) Antifungal activities against AIDS-related fungal
infections
Rhizomes Phongpaichit et al., [66]
(B) Inhibition of spoilage and aflatoxin producing
fungi Rhizomes
Pattaratanawadee et al.,
[44]
(13) Inhibition of Ca2+ signal in yeast model Rhizomes
Wangkangwan et al.,
[67]
(14) Antiviral activities
(A) Anti-HIV-1 protease activity Rhizomes
Tewtrakul et al. [26, 27]
Cheenpracha et al. [30]
(B) Inhibition of dengue NS2B/NS3 protease Rhizomes Tan et al., 2006
(C) Antifoot and mouth disease virus Rhizomes
Chungsamarnyart et al.
[68]
(15) Anti-inflammatory
(A) TPA-induced ear oedema Rhizomes Tuchinda et al. [25]
(B) Inflammation by nitric oxide (NO),
prostaglandin E2 (PGE2), and tumour necrosis
factor alpha (TNF-α)
Rhizomes Tewtrakul et al. [69]
(C) Anti-inflammation eﬀect caused by
Opisthorchis viverrini
Rhizomes
(powder)
Boonjaraspinyo et al.
[70]
(16) Inhibition of platelet-activating factor (PAF)
receptor binding eﬀect
Rhizomes Jantan et al. [71]
5. Oral Infections
5.1. Inhibition of Biofilm Formation by Oral Pathogens.
Biofilm formation on teeth surfaces is caused by multiple
species of oral bacteria, the primary colonisers being mutant
Streptococci [72]. Biofilm formation is associated with several
acute and chronic infections such as dental caries, gingivitis,
and periodontitis and potentially contributes to antibi-
otic treatment failure against Streptococcus pyogenes [48].
In 2008, Limsuwan and Voravuthikunchai demonstrated
that the extracts from B. rotunda, Eleutherine americana,
and Rhodomyrtus tomentosa exhibited antibiofilm activity
towards S. pyogenes at subinhibitory concentrations (1/32–
1/2 MIC) for E. americana (7.81–125 μg/mL), R. tomentosa
(0.24–7.81 μg/mL), and B. rotunda (1/2 MIC of 7.8 μg/mL).
Antiquorum sensing test revealed that B. rotunda showed
no inhibition activity, while R. tomentosa displayed strongest
antiquorum eﬀect followed by E. americana with moderate
eﬀect. However, microbial adhesion to hydrocarbon assay
showed no changes in the cell-surface hydrophobicity of
treated bacteria [48].
The following year, Yanti et al. [49] reported the anti-
biofilm property of B. rotunda extracted panduratin A,
which was found to prevent and reduce the spread of
multispecies oral bacteria in human mouth. The MIC
of panduratin A was determined using the Clinical and
Laboratory Standards Institute (CLSI) broth microdilution
assay. Mucin-mixed panduratin A at concentrations between
0.5 and 40 μg/mL was coated on 96-well plates, followed
by inoculation of three multispecies bacteria, Streptococcus
mutans, Streptococcus sanguis, and Actinomyces viscosus, and
incubated overnight at 37◦C to allow biofilm formation.
Biofilm reduction eﬀect was determined by further treating
the bacteria with diﬀerent concentrations of panduratin A
(0.2–10 μg/mL) for up to 60mins. Panduratin A exhibited
bacteria reduction eﬀect at MIC of 1 μg/mL and bactericidal
eﬀect against multispecies planktonic cells at 2X MIC, 8
hours after treatment. Reduction of biofilm formation was
>50% at 8X MIC, whereas mass reduction of biofilm was
observed within 15mins at a concentration of 10 μg/mL [49].
These results suggested that panduratin A can potentially be
used to prevent colonisation of multispecies bacteria, under
a dose-dependent manner, and that its eﬀect is equal to
commercially available synthetic drugs such as chlorhexidine
gluconate [49].
5.2. Antiperiodontitis Activity of B. rotunda Extract. A study
conducted by Yanti et al. [49] on the ethanolic extract of
B. rotunda revealed the suppressive eﬀect of this extract on
the expression of matrix metalloproteinases (MMPs) 2 and
9, both of which are overexpressed by gingival fibroblasts
that are activated by Porphyromonas gingivalis during chronic
periodontitis. They first described the inhibition of RNA and
protein expression of MMP-9 by the B. rotunda ethanolic
extract, which were 45% and 52%, respectively. Inhibition
of MMP-9 was found to occur through downregulation of
mitogen activated protein kinases (MAPK) phosphorylation
(ERK1/2, p38, and JNK phosphorylation), thereby reducing
the expression of Elk1, c-Jun, and c-Fos transcriptional
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factors. MMP-9 gene-regulating factors, AP-1 and NF-κB,
were also blocked [49].
In 2010, Yanti et al. further demonstrated the decrease
in RNA and protein expression of MMP-2 in P. gingivalis
supernatant-treated human gingival fibroblast-1 (HGF-1),
and MMP-9 in P. gingivalis supernatant-treated oral epider-
moid cells (KB cells) in a dose-dependent manner, upon
treatment with the ethanolic extract of B. rotunda at 2 μg/mL,
5 μg/mL, and 10 μg/mL. Suppression of MMP-2 was found
to be mediated by downregulation of c-Jun N-terminal
kinase (JNK) and cyclic adenosine monophosphate (cAMP)
response element-binding (CREB) signalling pathways [50].
5.3. Inhibition of Candida albicans. C. albicans is a diploid
fungus responsible for oral thrush or oral candidiasis and is a
common infection observed in HIV patients. Several studies
have demonstrated the potential antifungal role of B. rotunda
in inhibiting C. albicans growth. A study conducted by
Cheeptham and Towers [51] revealed the antifungal activity
of B. rotunda ethanolic extract against C. albicans as well
as A. fumigatus. The activation of the antimicrobial activity
was found to be light mediated, as treatment performed
in the dark showed no fungal inhibition [51]. In 2010,
Taweechaisupapong et al. studied the antioral pathogen
activities of the oil and 95% ethanolic extracts of B. rotunda
and Piper sarmentosum. The extracts were screened against
4 oral pathogens, namely, Streptococcus mutans, Lactobacillus
sp., Aggregatibacter actinomycetemcomitans, and C. albican.
Results from their study showed that B. rotunda oil extract is
a potent inhibitor against all these pathogens, as compared
to B. rotunda ethanolic extract, and P. sarmentosum oil and
ethanolic extracts. The MIC for S. mutans, Lactobacillus sp.,
A. actinomycetemcomitans, and C. albicans was 2.0, 1.0, 0.5,
and 0.5mg/mL, respectively, for B. rotunda oil extract, while
P. sarmentosum oil did not show any inhibition. In fact,
B. rotunda oil extract showed faster killing activity towards
C. albicans than the commercial drug, nystatin, in a time-
kill curve study. Fungistatic activity was observed at con-
centrations of 1 and 1.5 times the MIC, whereas fungicidal
eﬀect was found at concentrations of 2 and 2.5 times the
MIC, with a reduction of more than 3 log10 CFU/mL after
60 and 44mins incubation, respectively [52]. These studies
show that B. rotunda could be a potentially good source of
antimicrobial agents in inhibiting oral microbes and fungal
infections.
5.4. Anticariogenic. Dental caries or tooth decay (cavity) is
a common disease caused by the oral bacteria Streptococcus
mutans and Lactobacillus. These acid-producing bacteria
cause damage to the tooth in the presence of fermentable
carbohydrates such as sucrose and fructose, which wash
away the mineral fluoride from the tooth, often resulting
in tooth ache, or to a severe extent, death. The anticari-
ogenic activity of B. rotunda was first described in 2004
by Hwang and colleagues. Antibacterial and bactericidal
activities of B. rotunda methanolic extract were determined
by well diﬀusion and viable cell count methods, respectively.
Antibacterial study revealed a dose-dependent increase in
the diameter of inhibition zones, with concentrations of
1mg/mL, 10mg/mL, and 20mg/mL producing inhibition
zones of 11mm, 13mm,and 14mm in diameter, respectively.
B. rotunda extract also showed rapid bactericidal activity
against S. mutans in 2mins at a concentration of 50 μg/mL,
rendering it practically important, given that application
in toothpaste and mouthwash should be fast and eﬀective
within minutes [53].
Further isolation and purification of B. rotunda rhizomes
yielded isopanduratin A, which was identified through
1HNMR. This compound conferred inhibitory properties
against S. mutans, having an MIC value of 4mg/L, which
was lower than some natural anticariogenic agents such as
green tea extract (125mg/L) and eucalyptol (500mg/L). At
20mg/L, the bacteria were completely inactivated within
1min. This compound also showed similar inhibitory activ-
ity towards S. sobrinus, S. sanguinis, and S. salivarius at an
MIC of 4mg/L. Microscopic observation through transmis-
sion of electron microscope revealed the destruction of the
bacterial cell wall and cytoplasmic membrane detachment
after treatment with 10mg/L isopanduratin A, suggesting
the potential application of isopanduratin A as a natural
anticariogenic agent to prevent cariogenic eﬀect on teeth
[54].
5.5. Candidal Adhesion Inhibitor. Candidal adhesion is an
essential mechanism for Candida species to adhere to the
oral surfaces to colonise the mouth and cause oral diseases.
Sroisiri and Boonyanit [55] recently reported that the
rhizome extract of B. rotunda could inhibit the adhesion of
Candida species on the denture acrylic surfaces in a dose-
dependent manner. Pretreatment of the dentures with B.
rotunda extract at concentrations of 25, 50 and 100mg/mL
significantly inhibited candidal adhesion by approximately
47%, 66%, and 74%, respectively. Ergo, it is theorised that
candidal adhesion can possibly be reduced by soaking acrylic
dentures in B. rotunda rhizome extract for 30mins [55].
5.6. Antihalitosis. Halistosis (or bad breath) is a condition
where the mouth produces an unpleasant odor when
exhaling. This situation is typically associated with oral
conditions such as gum diseases and oral hygiene. It can also
be caused by the odour from esophagus, tonsil, nose, and
stomach. Hwang et al. [56] have patented the optimum oral
wash formulation of antihalitosis, containing panduratin
derivatives from B. rotunda, that could reduce the eﬀect of
halitosis by 70–90% [56].
6. Inhibition of Biofilm Formation by
Intestinal Pathogens
Given the positive findings regarding the inhibitory activity
of B. rotunda against biofilm formation of several oral
pathogens, Rukayadi et al. further investigated its inhibitory
properties against enterococcal biofilm formation. Entero-
cocci, particularly E. faecalis and E. faecium, are common
Gram-positive cocci found typically in the intestinal tract
and are known to cause intestinal and urinary infections.
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By employing the CSLI guidelines, the MIC of panduratin
A was found to be 2 μg/mL while the MBC that eﬀectively
killed all the enterococci isolates was 8 μg/mL. At 4X MIC,
the compound caused bactericidal eﬀect after 30mins of
incubation, as determined by time-kill curve study. The MIC
of panduratin A was also lower than that of other com-
mercial antibacterial agents such as ampicillin (256 μg/mL),
tetracycline (64 μg/mL), gentamycin (512 μg/mL), and ery-
thromycin (256 μg/mL), indicating that it is more potent
than commonly administered antibiotics [57].
7. Antioxidant Activities
7.1. Inhibition of Lipid Peroxidation in Brain. Lipid peroxida-
tion is the oxidative degradation of lipid, which is a damaging
process as generation of peroxidation products leads to the
spread of free-radical reactions. Free-radicals are known
causes of pathological disturbances such as atherosclerosis
and myocardial infarction. The antioxidant activity of B.
rotunda rhizome was recently demonstrated by Shindo and
colleagues [29], who studied the free-radical scavenging
activities of six bioactive compounds from B. rotunda rhi-
zome extract; (−)-panduratin A, (−)-4-hydroxypanduratin
A, 2′,6′-dihydroxy-4′-methoxychalcone, 2′,4′-dihydroxy-6′-
methoxychalcone, 5-hydroxy-7-methoxyflavanone, and 5,7-
dihydroxyflavanone, on rat brain homogenate model. Lipid
peroxidation activity on these compounds, extracted using
CH2Cl2–MeOH (1 : 1) and purified by using hexene-
EtOAc (5 : 1) in silica gel column, revealed two potent
inhibitors, (−)-panduratin A (IC50 15 μM) and (−)-4-
hydroxypanduratin A (IC50 4.5 μM). Neuroprotective eﬀect
of these compounds was also demonstrated through L-
glutamate toxicity study. Four compounds, (−)-panduratin
A, 2′,6′-dihydroxy-4′-methoxychalcone, 2′,4′-dihydroxy-6′-
methoxychalcone, and (−)-4-hydroxypanduratin A, showed
high neuroprotective eﬀect with an eﬀective concentration
(EC50) of 13 μM, 37 μM, 48 μM, and 14 μM, respectively, as
compared to (+)-catechin (160 μM). The side chain struc-
tures of (−)-panduratin A and (−)-4-hydroxypanduratin A
are likely causes for the higher inhibitory activity of these 2
compounds [29].
7.2. Inhibition of Oxidative Damages by tert-Butylhydrop-
eroxide (t-BHP). Sohn et al. [58] reported the protec-
tive eﬀects of panduratin A against t-BHP, an organic
hydroperoxidant that initiates lipid peroxidation through its
metabolism to free-radical intermediates, causing oxidative
damage to cells. MTT cell viability assay showed a decrement
in HepG2 cell growth inhibition by t-BHP, whereas fluoro-
metric measurement revealed a dose-dependent reduction in
malondialdehyde (MDA) formation and glutathione (GSH)
depletion, upon treatment with panduratin A. Intracellular
reactive oxygen species (ROS) production was also reduced
from 665±11.79 (mean± standard deviation) to 170±30.62
when treated with 15 μM of the compound, further implying
the potential application of this compound as a natural
antioxidant [58].
8. Antiulcer Effect
B. rotunda is also used as a traditional medicine to treat
ulcer by local communities in Thailand and Indonesia.
The antiulcer eﬀect of B. rotunda methanolic extract and
its pure compound, pinostrobin, was recently explored by
Abdelwahab and coworkers [59]. B. rotunda extract and
pinostrobin exhibited cytoprotective eﬀects on ulcer-induced
rats, as evidenced by the reduction in ulcer area and mucosal
content. In addition, submucosal edema and leukocytes
infiltration were significantly reduced or prevented. The
antioxidant activity of pinostrobin was proven through its
ability to reduce the level of thiobarbituric acid reactive
substances (TBARS) and through ferric reducing antioxidant
power (FRAP) assay which gave a value of 116.11 ± 0.004
(mean ± standard deviation) [59].
9. Obesity Treatment
Obesity is a metabolic disorder that poses a global threat
to humans. Caused by fat accumulation due to improper
energy balance and lipid metabolism, obesity can cause
liver and cardiovascular diseases. Panduratin A, previously
determined to be a novel natural AMP-activated protein
kinase (AMPK) activator, was studied in attempts to decipher
the regulatory mechanisms involved in AMPK-PPARα/δ
signalling. AMPK is an enzyme that regulates cellular energy
through activation of LBK1 and Ca2+/calmodulin-dependent
protein kinase kinase β (CaMKKβ). The activation of AMPK
will increase the fatty acid oxidation by activating fatty
acid oxidation-related genes. This process will prevent lipid
synthesis via reduction of sterol regulatory element-binding
protein-1c (SREBP-1c) and PPARγ phosphorylation. When
50mg/kg/day of panduratin A was applied, AMPK sig-
nalling was found to be stimulated, nuclear translocation of
AMPKα2 induced, followed by activation of PPARα/δ, with
LKB1 being the key mediator of these eﬀects. Activation of
PPARα/δ increased fatty acid oxidation, resulting in weight
loss, and reduced fat pad mass as observed in the in vivo
obese mouse model. Moreover, these mice showed reduction
in fatty liver and an improvement in the serum lipid profiles.
Myofibre proportion and mitochondria content in muscles
were significantly increased, enhancing running endurance
[60]. Taken together, these results exemplify the usefulness
of panduratin A in treating obesity and associated metabolic
disorders.
10. Anti-Mutagenic Effect
Mutagens such as mutagenic heterocyclic amines [3-
amino-1,4-dimethyl-5H-pyrido [4,3-b]indole (Trp-P-1), 3-
amino-1-methyl-5H-pyrido [4,3-b]indole (Trp-P-2) and 2-
amino-1-methyl-6 phenylimidazo [4,5-b]pyridine (PhIP)]
are found in cooked food or processed meat and fish and can
cause chromosomal and DNA damages, increasing the risk
towards diseases such as cancer. In 2001, Trakoontivakorn
et al., in the collaboration with a Japanese research group,
tested the antimutagenic properties of six extracted bioactive
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compounds from B. rotunda rhizome against Trp-P-1, Trp-
P-2, and PhIP in Salmonella typhimurium TA98. All six
compounds, pinocembrin chalcone, cardamonin, pinocem-
brin, pinostrobin, 4-hydroxypanduratin A, and panduratin
A, exhibited potent antimutagenic eﬀects, having IC50 values
of 5.2 ± 0.4, 5.9 ± 0.7, 6.9 ± 0.8, 5.3 ± 1.0, 12.7 ± 0.7, and
12.1 ± 0.8μM, respectively, with Trp-P-1 as the mutagen.
Similar inhibition was also observed with Trp-2-P and PhIP,
with the N-hydroxylation of Trp-2-P being strongly inhibited
[23]. This shows that the purified flavonoids, chalcones, and
cyclohexenyl chalcone derivatives (CCD) from B. rotunda
strongly hinder mutagenesis.
11. Antitumour Necrosis Factor
Alpha (Anti-TNF-α)
Tumour necrosis factor-α is a pleiotropic inflammatory
cytokine that plays an imperative role in immune
response to bacterial, fungal, and viral infections, as
well as in the necrosis of specific tumours. Extensive
production of TNF-α gives rise to health problems such
as autoimmune or chronic inflammatory disorders,
for instance, rheumatic arthritis. Morikawa et al. [35]
recently reported that prenylchalcones and prenylflavanones,
extracted from B. rotunda, could inhibit TNF-α. They
found that (+)-krachaizin B, (−)-krachaizin B, (+)-
4-hydroxypanduratin A, (−)-4-hydroxypanduratin A,
(+)-isopanduratin A,(−)-isopanduratin A, alpinetin, car-
damonin, and 2,6-dihydroxy-4-methoxydihydrochalcone
showed strong inhibition towards TNF-α on L292 cells at
10 μM, whereas (+)-krachaizin B, (−)-krachaizin B, (+)-
panduratin A, (−)-panduratin A, (+)-4-hydroxypanduratin
A, (−)-isopanduratin A, and geranyl-2,4-dihydroxy-
6-phenylbenzoate strongly inhibited the activity of
aminopeptidase N [35].
12. Anticancer/Antitumour
12.1. Breast Cancer and Colon Cancer Prevention. Breast and
colon cancers are among the leading causes of cancer
deaths worldwide. Despite the extensive ongoing research
in finding an eﬀective treatment regime or anticancer
drug to fight these diseases, researchers are still far from
uncovering a breakthrough, due in part to the lack of
knowledge on the physiology of these cancers. Nevertheless,
many current researches are still focused on natural plant
herbs as potential targets in anticancer drug development,
with B. rotunda being amongst them. Kirana et al. [61]
screened through eleven species of Zingiberaceae and found
B. rotunda and Zingiber aromaticum to exhibit the highest
inhibition towards MCF-7 breast cancer and human HT-
29 colon cancer cell growth, with the IC50 values being
21.3±0.3μg/mL and 32.5±1.5μg/mL, and 20.2±1.8μg/mL
and 11.8 ± 1.0μg/mL, respectively. Morphological studies
of the cells suggested death by apoptosis, as evidenced by
the appearance of membrane blebs, nuclear condensation,
and formation of apoptotic bodies [61]. Further evaluation
of another compound, panduratin A, on the same cell
lines revealed potent inhibitory properties as well. The IC50
values for MCF-7 and HT-29 cells were determined to
be 3.75 μg/mL and 6.56 μg/mL, respectively. Cell cycle and
proliferation studies showed that 71% of the cells were
arrested at G0/G1 after treatment with panduratin A, as
compared to 33% for untreated cells. Additionally, animal
study showed that this compound was nontoxic to the rats
as no obvious weight loss was observed, and the aberrant
crypt foci formation, although reduced, was not significantly
diﬀerent as compared to the control [62]. In 2004, Zaeoung
et al. reported cytotoxic activities of B. rotunda volatile oils
against breast cancer MCF-7 (IC50 31.7 ± 5.4μg/mL) and
LS174T colon cancer (IC50 12.0± 1.6μg/mL) cell lines [28].
In a separate study, Jing and colleagues demonstrated
that B. rotunda possessed the strongest inhibitory eﬀects
against CaOV3 ovarian cancer (IC50 71±1.41 μg/mL),
breast cancer MDA-MB-231 (IC50 66.5 ± 2.12μg/mL),
MCF-7 (IC50 51 μg/mL), HeLa cervical cancer
(IC50 65.5 ± 2.12μg/mL), and HT-29 colon cancer (IC50 52
± 4.24 μg/mL) cell growth as compared to three other
Boesenbergia species, B. pulchella var attenuate, and B.
armeniaca [39]. Cell cycle analysis on treated MCF-7 cells
revealed B. rotunda to eﬀectively arrest cells at sub-G1 phase,
whereas B. pulchella var attenuate arrested the cell cycle at
G2/M phase [73].
12.2. Inhibition of Prostate Cancers. In 2006, Yun et al.
demonstrated that treatment with panduratin A could
inhibit the growth of prostate cancer cell lines (PC3 and
DU145) in a time and dose-dependent manner, with IC50
values of 13.5 and 14 μM for PC3 and DU145 cells, respec-
tively. Immunoflourescence assay showed that panduratin
A triggered the induction of apoptosis in both cell lines,
through the inhibition of apoptotic-related procaspases 3,
6, 8, and 9. Apoptosis was suggested to occur via the
mitochondrial-dependent pathway, as evidenced by the
increase of Bax : Bcl-2 ratio by 6- and 15-fold for PC3
and DU145 cells, respectively, and the upregulation of Fas
death receptor and TNF-related apoptosis-inducing ligand
(TRAIL). Cell cycle analysis revealed cell cycle arrest at G2/M
phase in a dose-dependent manner. Moreover, immunoblot
analysis showed induction of p21WAF/Cip1 and p27Kip1, and
downregulation of cdks 2, 4, and 6, and cyclins D1 and E
[64]. These findings suggest that panduratin A could be a
potential therapeutic agent against prostate cancer.
12.3. Antilung Cancer. Aside from the anticancer properties
towards breast, colon, and prostate cancer, panduratin A also
exhibited inhibitory activities against A549 human nonsmall
cell lung cancer cells. The IC50 value of this compound
was 4.4 μg/mL, as determined by MTT assay, whereas cell
cycle analysis via flow cytometer showed cell cycle arrest at
mitotic/M phase. Panduratin A also acted as nuclear factor
kappa beta (NF-κB) inhibitor, as treatment at apoptosis-
inducing concentration was found to inhibit translocation of
NF-κB from cytoplasm to nuclei by the activation of tumour
necrosis factor alpha (TNF-α) [65].
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12.4. Antileukemia. B. rotunda rhizome has been suggested
to possess antileukemic property, as demonstrated by Sukari
and colleagues [34]. Cytotoxicity assay on B. rotunda extracts
and five flavonoid derivatives, pinostrobin, pinocembrin,
alpinetin, cardamonin, and boesenbergin A, revealed that
most extracts and pure compounds were able to inhibit the
growth of HL-60 cancer cell line, particularly the chloroform
extract and boesenbergin A [34].
13. Antifungal Activities
13.1. Antifungal Activities against AIDS-Related Fungal Infec-
tions. AIDS is one of the major infectious diseases in
Thailand and is most commonly transmitted sexually. HIV
patients are susceptible to fungal infections such as can-
didiasis by Candida species, cryptococcosis by Cryptococcus
species, and histoplasmosis by Histoplasma capsulatum,
and traditional herbs are typically sought after as natural
treatment. Phongpaichit et al. [66] reported that the chlo-
roform extract from rhizome of B. rotunda could inhibit
the propagation of Candida neoformans and Microsporum
gypseum but showed low eﬀect against C. albicans by using
antifungal assay. From the disc diﬀusion assay, the plant
extract of B. rotunda showed the smallest diameter range as
compared to other plant extracts, with inhibition zones of
8.0 ± 0.1–0.6mm and ±9.0mm in diameter for C. albicans
and Cryptococcus neoformans, respectively. The MIC for the
chloroform extract of B. rotunda was 64 μg/mL against C.
neoformans and M. gypseum, which was determined to be the
lowest and most active among the plant extracts in inhibiting
fungal growth. The methanolic extract, on the other hand,
had an MIC of 128 μg/mL against C. neoformans. Conversely,
both extracts had little inhibition against C. albicans (MIC >
512 μg/mL) [66].
13.2. Inhibition of Spoilage and Aflatoxin Producing Fungi.
Food spoilage due to spoilage fungi, such as aflatoxin fungi,
is a major concern among consumers. Pattaratanawadee et
al. [44] showed that the ethanolic extract of B. rotunda could
inhibit spoilage fungi activities (Aspergillus flavus, Aspergillus
niger, Aspergillus parasiticus, and Fusarium oxysporum) with
MICs of >10% (v/v), 8% (v/v), 10% (v/v), and <8% (v/v),
respectively [44]. This shows that B. rotunda is a good choice
to inhibit the growth of certain spoilage fungi.
14. Inhibition of Ca2+ Signal in Yeast Model
Ca2+ signalling is one of the crucial physiological pathways in
most living organisms, playing imperative roles in regulating
diverse cellular processes such as T-cell activation and
apoptosis. Extensively studied in the yeast Saccharomyces
cerevisiae, Ca2+ signalling is implicated in the regulation of
G2/M cell cycle progression, and inappropriate activation of
this signalling pathway can cause physiological and devel-
opmental defects. Wangkangwan et al. [67] reported that
the bioactive compounds from the crude rhizome extract
of B. rotunda could inhibit Ca2+ signalling in S. cerevisiae
mutant zds1Δ strain. Further purification of the crude extract
led to isolation of three compounds, namely, pinostrobin,
alpinetin, and pinocembrin chalcone. Yeast proliferation
assay showed significant inhibition by pinostrobin (low
cytotoxicity), alpinetin (high cytotoxicity), and pinocembrin
chalcone (high cytotoxicity) with MICs of <0.5, 1, and 0.5,
respectively. Given the low toxicity of pinostrobin at 1mM,
it was further subjected to biochemical studies and was
found to relieve hyperactivation of Ca2+ signals in yeast,
which is responsible for abnormal morphology and growth
arrest at G2 phase. Flow cytometry analysis revealed that
treatment with 1mM pinostrobin prevented G2 arrest of
yeast cells, and normal morphology characterised by equal
nuclei distribution and the absence of abnormal budding was
observed [67].
15. Antiviral Activities
15.1. Anti-HIV-1 Protease Activity. The HIV-1 protease
(aspartyl protease class), a highly conserved protein com-
ponent for viral maturation, propagation, and infectivity
in the human body, is a promising drug target currently
under extensive research for the development of drugs
and therapeutics to combat HIV/AIDS. The anti-HIV
protease activity of B. rotunda rhizomes was previously
characterised by Cheenpracha et al. [30]. Purification of
methanolic extract of B. rotunda rhizomes yielded cyclohex-
enyl chalcones panduratin A, panduratin C, hydroxypan-
duratin A, and chalcone derivatives, helichrysetin, 2′,4′,6′-
trihydroxyhydrochalcone, and uvangoletin. Their results
showed that hydroxypanduratin A and panduratin A exhib-
ited high inhibition, with IC50 values of 5.6 μM and 18.7 μM,
respectively, as compared to other bioactive compounds
which showed weaker inhibition. Structure activity rela-
tionship (SAR) study revealed that the eﬀectiveness of the
HIV-1 protease inhibition is related to the hydroxylation
and prenylation of chalcones [30]. In a separate study,
Tewtrakul and colleagues [26] investigated the anti-HIV
protease activity of chloroform, methanol and water extracts
of several traditional herbs used by Thai locals as self-
medication for AIDS. The chloroform extract of B. rotunda
exhibited the most potent inhibition against HIV-1 protease
(64.92±4.75%), followed by methanolic extract with 51.92±
0.22% inhibition as compared to other plant species [26].
In another study, four flavonoids, namely, pinostrobin,
pinocembrin, cardamonin, and alpinetin, were isolated from
the ethanolic extract of B. rotunda rhizomes. Antiviral assay
showed that cardamonin exhibited the highest inhibition of
75.11± 1.44% with an IC50 value of 31.0 μg/mL [27]. There-
fore, cardamonin, panduratin A, and hydroxypanduratin A
are potential drug targets to inhibit HIV-1 protease activity.
15.2. Inhibition of Dengue NS2B/NS3 Protease. Dengue virus
serotype-2 (Flaviviridae family) is one of the four dengue
serotypes responsible for causing dengue fever, dengue
haemorrhagic fever, and dengue shock syndrome worldwide.
To date, there is no commercial vaccine available to circum-
vent the spread of the virus. Research is still underway to
develop an eﬀective vaccine or drug and natural compounds
are currently among the important antiviral resources.
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In 2006, Tan et al. studied the inhibition activity
of CCD and flavonoids from B. rotunda against dengue
NS2B/NS3 protease cleavage. Based on their results, CCD
such as 4-hydroxpanduratin A and panduratin A showed
the strongest inhibition, with inhibition constant, Ki,
values of 21 μM and 25 μM, respectively, as compared
to pinocembrin, pinostrobin, cardamonin, and alpinetin.
4-Hydroxypanduratin A had higher inhibition percent-
age (78.1 ± 0.1%) than panduratin A (66.7 ± 0.1%)
at a low concentration of 80 ppm, when using sub-
strate 1 [tert-butyloxycarbonyl-glycyl-L-arginyl-L-arginine-
4-methylcoumaryl-7-amide (Boc-Gly-Arg-Arg-MCA)] to
cleave the protease. Although pinocembrin and carda-
monin did not show high inhibition, combination of both
compounds, however, managed to inhibit the NS2B/NS3
protease activity by 81.8 ± 0.3% at 400 ppm. For substrate
2 (Boc-Gln-Arg-Arg-MCA), 4-hydroxypanduratin A still
showed the highest inhibition at 90% at a concentration of
120 ppm, compared to pinostrobin and panduratin A, which
nonetheless showed good inhibition as well [74]. Thus, these
compounds may serve as potential inhibitors for dengue-2
NS2B/NS3 protease.
15.3. Antifoot and Mouth Disease Virus (Anti-FMDV). Foot
and mouth disease (FMD) is caused by the infection of
a picornavirus called the Foot and Mouth Disease virus
(FMDV). FMDV infects cloven-hoofed animals such as
bovids, and also sometimes humans. In Thailand, B. rotunda
is typically used as an anti-FMDV natural herb by local folks.
In 2007, a group of Thailand researchers investigated the
antiviral activity of 42 local herb extracts against FMDV,
24 of which exhibited anti-FMDV activity. While the most
potent extracts were the crude extracts of Morinda elliptica
(TCID50 of 1 × 103.65) and Morinda citrifolia (TCID50 of
1 × 103.35) at concentrations of 0.39 μg/μL and 0.19 μg/μL,
respectively, B. rotunda also showed anti-FMDV activity with
TCID50 1 × 102.14 at 0.012 μg/μL concentration [68].
16. Anti-Inflammatory
Inflammation is a biological process that is activated in
response to extracellular stimulants such as pathogens and
chemicals, to mitigate the eﬀects or heal the organism.
B. rotunda has been traditionally used in treating sev-
eral inflammatory-related diseases such as gout, allergy,
and peptic ulcer. Scientific research has proven the anti-
inflammatory properties of this plant, as discussed below.
16.1. TPA-Induced Ear Oedema. The inflammatory activity
of B. rotunda was studied on rats with 12-O-tetradecanoyl
phorbol-13-acetate (TPA)-induced ear oedema. (−)-
Hydroxypanduratin A and (−)-panduratin A, isolated
from the chloroform extract of B. rotunda red rhizomes,
were found to exhibit strong anti-inflammatory activities
compared to the other extracted compounds, sakuranetin,
pinostrobin, pinocembrin, and dihydro-5,6-dehydrokawain.
The IC50 values for (−)-Hydroxypanduratin A and (−)-
panduratin A were 84 μg/ear and 12 μg/ear, respectively.
(−)-hydroxypanduratin A inhibited TPA-induced ear
oedema by 73% at 2000 μg/ear concentration and 10 hrs
treatment, whereas 94% inhibition was obtained with
(−)-panduratin A treatment at the same concentration
and incubation time point. Ear oedema thickness was also
significantly reduced to 48 ± 6 μm from 94 ± 6 μm and
11 ± 4 μm from 81 ± 8 μm for (−)-hydroxy panduratin
A and (−)-panduratin A treated rats, respectively [25].
Further investigation is warranted to study the mechanisms
of action and targets of both compounds with regards to
their anti-inflammatory activities.
16.2. Inflammation by Nitric Oxide (NO), Prostaglandin
E2 (PGE2), and Tumour Necrosis Factor Alpha (TNF-
α). In 2009, Tewtrakul et al. reported that the extracts
of Kaempferia parviflora and B. rotunda exhibited anti-
inflammatory eﬀects through the inhibition of nitric oxide
(NO), prostaglandin E2 (PGE2), and tumour necrosis factor
alpha (TNF-α). NO acts as an inflammatory intermediator
within the human metabolic processes, defending against
intracellular and extracellular stimulants. Excess of this
molecule; however, will induce pathogenesis in cells and
form reactive free-radical upon reaction with other radicals.
These reactive radicals cause direct damage to the function
of normal cells. PGE2 and TNF-α are also inflammatory
inter-mediators involved in inflammation and carcinogen-
esis. Panduratin A and hydroxypanduratin A, which were
purified from B. rotunda methanolic extract, showed strong
inhibitory activity against NO, with IC50 values of 5.3 μM
and 13.3 μM, respectively, compared to the most potent
compound of K. parviflora which was 5-hydroxy-3,7,3′,4′-
tetramethoxyflavone (IC50 16.1 μM). High inhibition against
PGE2 production was observed, whereby both panduratin
A and hydroxypanduratin A had IC50 values of 10.5 μM
and 12.3 μM, respectively, which was comparable to that
of 5-hydroxy-3,7,3′,4′-tetramethoxyflavone (IC50 16.3 μM).
Conversely, only a moderate inhibitory activity on TNF-
α was observed for all three compounds, panduratin A
(IC50 60.3 μM), hydroxypanduratin A (IC50 57.3 μM), and
5-hydroxy-3,7,3′,4′-tetramethoxyflavone (IC50 > 100 μM)
[69].
16.3. Anti-Inflammatory Eﬀect Caused by Opisthorchis
viverrini. Opisthorchis viverrini is a parasite from the Opist-
horchiidae family that causes cholangiocarcinoma in
humans. It is disseminated through consumption of raw
and uncooked fish and can cause inflammation during the
infection. Boonjaraspinyo et al. [70] reported that B. rotunda
rhizome could inhibit inflammation caused by O. viverrini
and induced by N-nitrosodimethylamine administration
(NDMA) in rats. Histopathological study showed that
the liver tissues of normal and B. rotunda-treated rats
exhibited similar morphology (no inflammation observed)
compared to NDMA-treated (higher cytotoxicity eﬀect)
and O. viverrini-infected rats which showed inflammation
around the hepatic bile ducts after one month. Upon
treatment with B. rotunda plant extract, O. viverrini-infected
and NDMA-treated liver cells showed a reduction in the
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inflammatory cells surrounding the hepatic bile ducts,
which correlated with the decrement in the levels of serum
alanine transaminase and direct bilirubin, but not of alkaline
phosphatase, which remained the same level as untreated
group [70].
17. Inhibition of Platelet-Activating
Factor (PAF) Receptor Binding Effect
PAF is a phospholipid mediator that is involved in many
negative physiological functions and pathological condi-
tions such as bronchoconstriction-induced asthma, hyper-
acute organ-transplant rejection, gastrointestinal ulcera-
tion, thrombosis, and allergic reaction. Jantan et al. [71]
showed that the PAF receptor binding eﬀect could be
inhibited by using local medicinal herb extracts obtained in
Malaysia. They successfully identified eleven plant extracts
(Alpinia galangal, B. rotunda,Curcuma anthorrhiza,Curcuma
aeruginosa, Zingiber oﬃcinale, Zingiber zerumbet, Cinnamo-
mum altissimum, Cinnamomum pubescens, Goniothalamus
malayanus, Momordica charantia, and Piper aduncum) that
significantly reduced the binding eﬀect of PAF on rabbit
platelets (IC50 values ranging from 1.2 to18.2 μg/mL) with
more than 60% inhibition. The strongest inhibition eﬀect
was shown by Z. zerumbet with IC50 of 1.2± 2.0 μg/mL (96.4
± 1.4% inhibition), followed by B. rotunda with IC50 of 8.6±
2.6μg/mL (80.4 ± 4.1% inhibition), when compared with
cedrol (control) which showed 85.2±2.4% inhibition at IC50
value of 2.4± 1.3μg/mL [71]. Therefore, these plant extracts
can be used to potentially treat PAF-mediated diseases.
18. Wound Healing Properties
Ethanolic extracts of B. rotunda rhizome have been shown
to accelerate wound healing in rats [75]. Visually, it was
shown that wounds dressed with rhizomes extract and
Intrasite gel significantly healed earlier than those treated
with vehicle. Histological analysis of healed wounds dressed
with rhizomes extract showed comparatively less scar width
at wound closure and healed wound contained less inflam-
matory cells and more collagen with angiogenesis compared
to wounds dressed with vehicle only.
From the empirical results mentioned previously, B.
rotunda contains potential bioactive compounds with mul-
tiple medicinal properties that can prevent, mitigate, or treat
various diseases as well as prevent them from spreading.
Table 2 summarises the inhibition activities of various B.
rotunda extracts towards diseases investigated and reported
by scientists worldwide.
19. Current Research on B. rotunda
19.1. Tissue Culture and Metabolite Engineering. In vitro
culture provides an immediate source of compounds in a
sustainable approach and as study subjects for molecular
biology, crop improvements, and genetics studies. Further-
more, it oﬀers a feasible platform with defined, controllable
chemical and physical conditions for metabolite engineer-
ing. Rao and Ravishankar [76] described a nonredundant
list of plant-derived pharmaceuticals and highlighted the
importance of the availability of contaminant-free samples,
optimum multiplication, and regeneration protocol for
metabolite engineering studies. With that, uniform quality
and yield of the compounds could be achieved without
problem with variation due to seasonal and geographical
reason [76].
Optimization of the culture conditions for B. rotunda
has been carried out by Tan et al. [77]. By manipulat-
ing the concentration of the plant growth regulator, 2,4-
dichlorophenoxyacetic acid (2,4-D), inMurashige and Skoog
[78] nutrient medium, Tan et al. [77] have successfully
induced somatic embryo from meristematic tissue of the
young plant. Somatic embryogenesis is a process whereby
a somatic cell undergoes development analogous to the
zygotic embryo and regenerates into a clonal plant. With
the medium formulation, 23.3± 4.3% of embryogenic callus
formed, and the plantlet regeneration rate was 6.6 ± 0.1
plantlets from a callus aggregate of 1 cm diameter. This
finding has made somatic embryogenesis a model system to
mass propagate identical cell/tissue samples of B. rotunda for
metabolite engineering.
Besides somatic embryogenesis, another route of
plantlets regeneration of B. rotunda has been investigated.
Yusuf et al. [79] reported a mass production method
from young shoot bud in MS medium with sucrose
(30.0 g/L), gelrite (2.0 g/L), diﬀerent concentrations of
6-benzylaminopurine (BAP), and α-naphthaleneacetic acid
(NAA). Combination of 2.0mg/L BAP and 0.5mg/L NAA
was found to be the best treatment for callus induction while
multiple shoots (90%, 5 shoots/explant) were induced from
day 10 to 14. In all treatments, roots spontaneously grew
after 10–14 days. Acclimatization of the in vitro plantlets in
soil was successfully performed.
Cell culture in liquid suspension is also an impor-
tant alternative source for metabolite engineering, mainly
owing to the fast propagating rate and ease of scaling-up
[80]. Furthermore, secondary metabolites accumulation in
suspension culture can be manipulated and enhanced by
external chemical and physical treatments with simplicity.
Direct contact between cell and nutrients or treatment agents
present in the liquid media permits a quick response of the
cell.
Chemical treatments such as nutrient level, sucrose level,
plant growth regulator (PGR), precursor, and substrate feed-
ing are the common methods facilitating the enhancement
of compound yield in suspension cultures. By modifying
growth-associated factors such as sucrose level, nutrient level
especially phosphate and nitrogen composition, and the
addition of diﬀerent types of PGR, productivity of both
biomass and compounds could be increased [81]. On the
other hand, relative productivity of compounds per dry
weight of cell biomass could be enhanced with nongrowth-
related precursors and elicitors.
Precursors are substrates or intermediates found in the
biosynthesis pathways from which the secondary metabolites
formed [82], while elicitors are physiological stimuli from
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various abiotic or biotic sources that trigger secondary
metabolites accumulation [83]. Metal salts and inorganic
ions are common abiotic elicitors used in treatments of plant
cell cultures for compounds enhancement. Biotic elicitors
include microbial cells or components of microbial cell and
even plant signalling molecules or compounds such as yeast
extract (YE), salicylic acid, and methyl jasmonate.
Zhao et al. [84] examined the eﬀects of four classes of
biotic and abiotic elicitors, heavy metal ions (cobalt, silver
nitrate, and cadmium chloride), polysaccharides from YE
and chitosan, salicylic acid, methyl jasmonate, and sorbitol
on the production of diterpenoid tanshinones in Salvia
miltiorrhiza cell culture. Amongst the treatments, 25 μM
Ag+ (silver nitrate), 25 μM Cd+ (cadmium chloride), and
100mg/L polysaccharide from YE successfully enhanced
tanshinone production by more than ten fold compared
to the control. Interestingly, the authors also reported
suppressed cell growth with a decrease in biomass yield
by about 50% in treated S. miltiorrhiza cell culture. In
another example, treatment of Taxus chinensis cells with Ag+
following adaptation in chitosan through several subcultures
resulted in a 4.6-fold increase in paclitaxel production
compared to the unadapted cells [85]. The authors also
suggested that the treatment using elicitors needed to be
optimized and explored thoroughly for promising results.
Physical treatments such as stress factors, light sources,
modification of culture environment and electric current,
and Pulsed Electric Field (PEF) methods are also widely
used for metabolite engineering in plant cell cultures [86].
Kaimoyo et al. successfully enhanced the production of
medicarpin by 168-fold in cell suspension [87].
Cai et al. [88] examined the eﬀects of elicitors and
high hydrostatic pressure on secondary metabolism of Vitis
vinifera suspension culture. The authors used the concentra-
tion of phenolic compounds as a measure of the secondary
metabolism level and found that it was significantly higher
than in the control when treated with ethephon. When the
treatment was carried out with combination of ethephon
and high hydrostatic pressure, extracellular phenolic acids
and 3-O-glucosyl-resveratrol were increased. The results
showed that hydrostatic pressure can be used for compound
secretion into the liquid medium. Cai et al. [89] further
explained that high hydrostatic pressure might alter the
permeability of cell/membrane and cause secretion of the
compounds as a defense response of plant cells. In V. vinifera
cv. Chasselas 9 and Vitis berlandieri cell suspension cultures
in a 2 L stirred bioreactor, 90% of the total resveratrol can be
secreted into the liquid medium [90].
In conclusion, with the availability in vitro sources for B.
rotunda, the study and enhancement of secondarymetabolite
production can be robustly performed and the bioreactor
technology could be employed for maximising the yield in
the near future.
19.2. Chemical Syntheses of Bioactive Compounds Isolated
from B. rotunda . The syntheses of flavonoid compounds
derived from B. rotunda have been well documented. A
review on the stereoselective synthesis of flavonoids has been
reported [91]. Although important progress has been made
in the syntheses of these compounds, the systematic study of
B. rotunda-derived flavonoids, that is, (−)-pinostrobin and
(±)-panduratin A is still hampered by the inaccessibility of
enantiomeric pure starting materials.
The enantioselectivity of (−)-pinostrobin was first re-
ported by Hodgetts [92]. The method was based on an
intramolecular Mitsunobu cyclisation of the chiral hydrox-
yphenol 3, which was prepared from the Weinreb amide
2 and the methoxymethyl (MOM)-protected phenol 1
(Scheme 1). Subsequent cleavage of the protecting groups
on 3 allowed the intramolecular Mitsunobu cyclisation to
produce methoxylated pinostrobin 4. Finally, regioselective
demethylation of 4 with aluminium chloride gave enan-
tiomeric pure (−)-pinostrobin in 60% overall yield from 3.
Recently Korenaga et al. have described an eﬃcient
method to synthesise (+)- and (−)-pinostrobin via rhodium-
catalysed asymmetric 1,4-addition of phenylboronic acid
to 5,7-dimethoxychromone 6 (Scheme 2). The reaction in
toluene proceeded smoothly at room temperature in the
presence of 0.5% rhodium catalyst with electron-poor chiral
diphosphine MeO-F12-BIPHEP ((6,6′-dimethoxybiphenyl-
2,2′-diyl)bis[bis-3,4,5-trifluorophenyl)phosphine]) to pro-
duce the desired pinostrobin in high yield and high enan-
tioselectivity (90% yield, 99.6% ee) [93].
We have recently reported the synthesis of (±)-pan-
duratin A and its regioisomer (±)-isopanduratin A in four
steps from (E)-ocimene via a Diels-Alder cycloaddition
reaction (Scheme 3) [94]. However, attempts to use the chiral
auxiliaries or catalysts such as the CBS-oxazaborolidines
and MacMillan’s imidazolidinones for the enantioselective
synthesis of panduratin A were not successful.
Kavalactones such as (+)-kavain and yangonin are the
major components of kava extract (Piper methysticum)
and have shown a wide spectrum of pharmacological
activities [95–103]. Derivative of kavalactones such as 5,6-
dehydrokavain has been found in B. rotunda. The synthesis
of these six-membered unsaturated δ-lactones has generated
a widespread interest. Various synthetic routes to racemic
and enantiopure kavalactones have been studied via Aldol
reaction involving cinnamaldehydes but none of them are
generally applicable to the synthesis of oxygen-substituted
kavalactones such as yangonin [104–117].
Amaral and coworkers described a strategy to synthe-
sise yangonin and derivatives based on the Heck cross-
coupling reaction of pyrone 7 and aryl iodides 8 (Figure 5).
Reaction of the pyrone 7, aryl iodides, and 10mol% of
tetrakis(triphenylphosphine)palladium (0) in the presence of
Hu¨nig’s base in DMF under microwave irradiation (300 W)
for 5.5min produced the desired kavalactones in moderate
yields [118].
They also devised an alternative strategy to syn-
thesise kavalactones via Suzuki-Miyaura coupling reac-
tion between (Z)-6-(2-iodovinyl)-4-methoxy-5,6-dihydro-
2H-pyran-2-one 9 and aryl boronic acid 10 (Scheme 4).
However, the reaction which catalysed by Pd(OAc)2 and
2-(2,6-dimethoxyphenyl) dicyclohexylphosphine (S-Phos)
resulted in the formation of an E/Z mixture of cross-coupling
products.
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The synthesis of (−)-nicolaiodesin C (also known as
(−)-krachaizin A) has been reported by Banuelos and
coworkers [119]. Accordingly, the BrØnsted acid-assisted
Diels-Alder reaction of (1R)-(+)-camphor-derived chiral α′-
hydroxyenone 11 and myrcene 12 first produced an enan-
tiopure adduct 13. Subsequent reduction of the carbonyl
group in 13 with LiAlH4 and oxidative cleavage of the
resulting diol with Pb(OAc)4 provided aldehyde 14. Addition
of the lithium anion of MOM-protected methoxyresorcinol
15 to aldehyde 14 aﬀorded the alcohol 16. Finally, (−)-
nicolaiodesin C was obtained after oxidation of the alcohol
16 with periodinane in dichloromethane and deprotection
of the MOM group in acidic conditions (Scheme 5).
19.3. Drug Discovery through Bioinformatics. Some bioactive
compounds of B. rotunda had been studied computationally
by Othman et al. [120], Paul et al. [121], and Frimayanti
et al. [122]. Three flavanones, pinostrobin, pinocembrin,
and alpinetin, and four chalcones, pinostrobin chalcone,
pinocembrin chalcone, and cardamonin, had been sub-
jected to automated docking towards dengue virus type 2
NS2B/NS3 protease (Protein Data Bank id: 2FOM) to under-
stand the interactions of these reported inhibitors [123] with
the binding sites of the protease [120]. In this study, it was
reported that the estimated ΔG (free energy of binding)
for the flavanones were lower than those of their chalcone
derivatives. The automated docking experiments showed
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that all the ligands studied did not bind to the active site of
the protease, which are consistent with the bioassay results,
illustrating the noncompetitive inhibitory activities for most
of the ligands [74]. Through SAR analysis, it was also
suggested that the higher noncompetitive inhibitory activity
shown by pinostrobin compared to the other compounds
could be accounted for by H-bonding interaction with the
backbone carbonyl of Lys74, which is bonded to Asp75
(one of the catalytic triad residues). As shown in Figure 2,
the rigid structure of flavanone, the C5 hydroxyl and C7
methoxy groups on ring A, and the phenyl ring (B) was also
suggested to be important features to consider in designing
new compounds with potential inhibitory activities against
dengue virus type 2 NS2B/NS3 protease.
Another docking study was performed in 2011 by
Frimayanti et al. using 2FOM structure, and the homology
model of dengue virus type 2 NS2B/NS3 protease with
reported competitive inhibitors [74], 4-hydroxypanduratin
A and panduratin A from B. rotunda as reference com-
pounds. The derivatives of these compounds were then used
as ligands for docking, and subsequently, new competitive
inhibitors were designed based on the docking result. Based
on Figure 4, substitutions were performed individually on
positions 1, 2, 3, 4, and 5 of the benzyl ring A of 4-
hydroxypanduratin A and panduratin A. It was found that
substitutions at positions 4 and 5 gave the lowest and closest
energies to the reference compounds from the calculated
complexation energies, and new ligands were designed by
substituting various functional groups on these positions.
This strategy was suggested to be an early stage drug
discovery for identifying drug candidates.
In 2010 [121], Paul and Choudhury conductedmolecular
docking studies on the activity of naturally occurring
pyranochalcones on the transcriptional regulator enzyme
of Pseudomonas putida, a gram-negative bacteria that is
resistant to antibiotics. In his studies, the HTH-type tran-
scriptional regulator TTgR (Protein Data Bank id: 2UXI)
in P. putida (bound with phloretin) was taken as the target
for docking with pyranochalcones as ligands. One of the
pyranochalcones, boesenbergin A (Figure 3), was isolated
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Figure 4: Structures of 4-hydroxypanduratin A and panduratin A.
from B. rotunda rhizomes and reported as a highly potential
candidate to be active against the multidrug resistant strain
of bacteria. From the SAR analysis, the binding aﬃnity of
the pyranochalcones was found to increase with increasing
number of methoxy moiety in the aromatic part of the
ligands. In contrast, the eﬀect of the methoxy moiety
connected to the fused aromatic unit, seemed to be less
pronounced, could be due to steric hindrance. The results are
hoped to be useful in designing new series of drugs especially
against the antibiotic-resistant bacteria.
20. Protein Profile of B. rotunda
Since B. rotunda has many medicinal uses, it is important
to explore the molecular level of the biosynthesis of the
targeted plant metabolites, especially panduratin A and 4-
hydroxypanduratin A, that have high therapeutic values. In
2011, Chong et al. conducted a preliminary study using
proteomic approaches to extract the total protein from
the callus (normal and treated callus). This is the initial
step to obtain the protein profile of the callus that can
be used to analyse the protein expression level of the
callus after treatment with phenylalanine, a precursor of
phenylpropanoid biosynthesis pathway, to produce CCD,
through an unknown biosynthesis pathway in B. rotunda
[124].
21. Future Prospects of Plant-Based Drug
The ethnomedicinal usages of B. rotunda, supported by
strong scientific evidence of its potential medicinal proper-
ties, clearly justify that this plant should indeed be brought
to the next level of drug discovery studies, directed towards
metabolomics, genomics, transcriptomics, proteomics, and
bioinformatics aspects to further characterise the mecha-
nisms and pathways that contribute to its desired properties.
The wide inhibition range of B. rotunda against multiple
diseases such as cancers, microbes, viruses, and parasites
should be further explored through new drug discovery stud-
ies such as plant-derived compounds, polypharmacology,
drug-DNA/protein interactions, and, specific drug stability,
solubility, and delivery to the targeted organ, by using
nanotechnology.
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22. Conclusion
B. rotunda is a native ingredient in many Asian countries and
is used as a condiment in food. It is also used as traditional
medicine to treat several illnesses, consumed as traditional
tonic especially after childbirth, beauty aid for teenage girls,
and as a leukorrhea preventive remedy for women. Its fresh
rhizomes are also used to treat inflammatory diseases, in
addition to being used as an antifungal, antiparasitic, and
aphrodisiac among Thai folks. Its leaves are used by locals
to alleviate food allergic and poisoning. Moreover, AIDS
patients self-medicate themselves with B. rotunda to cure
the infection. With the advancement in technology, the
ethnomedicinal usages of herbal plants can be explained
through in vitro and in vivo studies to prove the activities
of the plant extracts. The current state of research on B.
rotunda clearly shows that the isolated bioactive compounds
have high potential in treating many diseases. With the
development of medicinal chemistry and bioinformatics, we
are well on our way to successfully develop plant-based
drugs. Molecular progressions further encourage scientists
to delve deeper into the biosynthetic pathways of B. rotunda
bioactive compounds to obtain a bigger picture of the whole
process, which in turn could accelerate the development of
better and stronger drugs to counter the diseases in the
future.
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